Gynecologic Cancer

The FDA granted accelerated approval to tisotumab vedotin-tftv for certain women with advanced cervical cancer.

The FDA cleared an investigational new drug application for a T-cell receptor therapy designed to treat adults with solid epithelial cancers that express Kita-Kyushu lung cancer antigen 1.

The FDA cleared an investigational new drug application for a chimeric antigen receptor T-cell therapy designed to treat women with relapsed epithelial ovarian cancer.

The FDA granted fast track designation to STRO-002 for treatment of certain women with advanced gynecologic cancer.

The FDA granted accelerated approval to dostarlimab-gxly for adults with mismatch repair-deficient recurrent or advanced solid tumors that progressed on or after prior treatment and who have no satisfactory alternative therapies.

The FDA granted priority review to pembrolizumab as adjuvant therapy for certain patients with renal cell carcinoma, according to the agent’s manufacturer.

Transvaginal ultrasound used to determine appropriateness of endometrial cancer biopsy missed nearly five times more cases of the disease among Black women vs. white women, according to a simulated cohort study published in JAMA Oncology.

Members of American Society for Radiation Oncology elected three new officers to ASTRO’s board of directors.

Andre Nussenzweig, PhD, received the ninth annual Basser Global Prize.

In this video, Christina M. Annunziata, MD, PhD, senior investigator at the National Cancer Institute, discussed results from the TOTEM trial presented at the ASCO Annual Meeting.